Renaissance Technologies’s Orchestra BioMed OBIO Stock Holding History

Renaissance Technologies’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$388K	Buy	90,000 +19,100	+27%	+$78.1K	﹤0.01%	2699
2026 Q1	$301K	Sell	70,900 -80,400	-53%	-$342K	﹤0.01%	2789
2025 Q4	$628K	Sell	151,300 -229,208	-60%	-$925K	﹤0.01%	2483
2025 Q3	$944K	Buy	380,508 +211,108	+125%	+$582K	﹤0.01%	2509
2025 Q2	$454K	Buy	+169,400	New	+$494K	﹤0.01%	2882
2023 Q3	–	Sell	-12,600	Closed	-$88K	–	3966
2023 Q2	$88K	Buy	+12,600	New	+$191K	﹤0.01%	3504

Other funds holding OBIO

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Renaissance Technologies's OBIO Position: Q2 2026 in Review

Renaissance Technologies increased its Orchestra BioMed (OBIO) stake by 27% in Q2 2026, buying an estimated $78.1K and bringing the position to 90,000 shares worth $388K. The position accounts for ﹤0.01% of the portfolio, ranked #2699.

Renaissance Technologies first reported a position in OBIO in Q2 2023 and has held it in 6 quarters since. The position peaked at $944K in Q3 2025. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

Renaissance Technologies held 90,000 shares of Orchestra BioMed worth $388K as of Q2 2026.
Renaissance Technologies bought 19,100 Orchestra BioMed shares in Q2 2026, an estimated $78.1K.
Orchestra BioMed made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2699 holding.
Renaissance Technologies first reported a position in Orchestra BioMed in Q2 2023 and has held it in 6 quarters since.
Renaissance Technologies's Orchestra BioMed position peaked at $944K in Q3 2025.
77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.